NAD Precursor Comparison: NMN, NR and Niacin Oral Bioavailability Head to Head

Three NAD⁺ precursors compete for shelf space in the longevity aisle: nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), and the original B3 vitamins (niacin and niacinamide). Each enters the NAD⁺ salvage or de novo synthesis pathway at a different step, and their oral pharmacokinetics differ more than supplement marketing suggests. Understanding which one actually elevates blood and tissue NAD⁺ — and at what dose — helps separate plausible interventions from expensive urine.

The biochemistry the labels skip

NAD⁺ can be made from tryptophan (de novo pathway), from niacin/nicotinic acid (Preiss-Handler pathway), or from nicotinamide, NR, and NMN (salvage pathway). NR is phosphorylated to NMN by nicotinamide riboside kinases (NRK1/NRK2) and then converted to NAD⁺. Orally administered NMN is thought to be largely dephosphorylated to NR in the gut wall before crossing into circulation, then re-phosphorylated intracellularly, although a putative NMN transporter (Slc12a8) remains debated [1]. Nicotinamide and niacin enter via separate enzymatic routes (NAMPT and NAPRT respectively).

What human pharmacokinetic data show for NR

Trammell and colleagues conducted the first single-dose human pharmacokinetic study of NR, showing dose-dependent increases in blood NAD⁺ of roughly 2.7-fold at 1,000 mg and sustained elevation with daily dosing [2]. Martens and colleagues then ran a randomized, placebo-controlled crossover in healthy middle-aged and older adults with 500 mg NR twice daily for six weeks, which doubled blood NAD⁺ and reduced systolic blood pressure modestly in a subgroup with mild hypertension [3]. A long-term safety study by Conze and colleagues confirmed tolerability over eight weeks at 1,000 mg/day [4].

What human pharmacokinetic data show for NMN

Yoshino and colleagues conducted the first peer-reviewed clinical trial of NMN in prediabetic postmenopausal women, finding that 250 mg/day for 10 weeks improved muscle insulin sensitivity but did not change muscle NAD⁺ levels detectably [5]. Igarashi and colleagues studied 250 mg/day NMN in older men over 12 weeks and reported elevations in whole-blood NAD⁺ metabolites with a favorable safety profile [6]. The combined picture suggests NMN and NR both raise blood NAD⁺, though the magnitude varies with assay method and matrix.

The niacin pathway most people forget

Pharmacologic niacin (nicotinic acid, 500-2,000 mg/day) raises NAD⁺ to a similar or greater degree than NMN or NR in skeletal muscle, as shown by Pirinen and colleagues in patients with mitochondrial myopathy, where one year of niacin raised muscle NAD⁺ 1.3 to 1.8-fold and improved muscle strength [7]. The trade-off is the well-known niacin flush, mediated by GPR109A and prostaglandin D2, which can be reduced with timing and slow-release formulations but not eliminated. Niacin is also the only NAD⁺ precursor with strong clinical-outcome data — for lipid-modifying effects, not for longevity end points.

Which raises NAD+ most, and does it matter?

Head-to-head pharmacokinetic data favoring one precursor over another in humans are limited. All three reliably raise whole-blood NAD⁺; what is not established is whether any of them produces clinically meaningful biological effects beyond correcting deficiency. Blood NAD⁺ is not the same as NAD⁺ in the cells where the biology actually happens, and translating a serum biomarker change into improved healthspan remains unproven. Marketing language conflating "raised NAD⁺" with "slowed aging" is unsupported by the trial evidence currently available.

The practical takeaway

NR and NMN have comparable evidence for raising blood NAD⁺ at common doses (500-1,000 mg NR, 250-500 mg NMN). Niacin produces a similar effect at much lower cost but with flushing. None of the three has demonstrated meaningful longevity or healthspan benefits in adequately powered human trials. People taking these supplements should track this literature carefully — the next five years of trial readouts will be informative.